Immunogenicity of DNA vaccine expressing GP5 of porcine reproductive and respiratory syndrome virus fused with VP22 of bovine herpesvirus 1.
- Author:
Wu ZHAO
1
;
Shao-Bo XIAO
;
Liu-Rong FANG
;
Yun-Bo JIANG
;
Yun-Feng SONG
;
Lin YAN
;
Xiao-Lan YU
;
Huan-Chun CHEN
Author Information
1. Laboratory of Animal Virology, College of Animal Medicine, Huazhong Agricultural University, Wuhan 430070, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, Viral;
genetics;
immunology;
Artificial Gene Fusion;
Female;
Mice;
Mice, Inbred BALB C;
Porcine Reproductive and Respiratory Syndrome;
prevention & control;
Random Allocation;
Vaccines, DNA;
genetics;
immunology;
Viral Envelope Proteins;
genetics;
immunology;
Viral Structural Proteins;
genetics;
Viral Vaccines;
genetics;
immunology
- From:
Chinese Journal of Biotechnology
2005;21(5):725-730
- CountryChina
- Language:Chinese
-
Abstract:
To enhance the immuogenicity of DNA vaccines expressing the GP5 protein of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), the tegument protein VP22 (encoded by VP22 gene) of Bovine Herpesvirus 1 (BHV-1), which has been demonstrated to exhibit the unusual protein transduction property, was fused to N-terminus of GP5 of DNA vaccine construct pCI-ORF5M, resulting in pCI-VP22-ORF5M expressing VP22-GP5 fusion protein. The expression of VP22-GP5 fusion protein was confirmed by both indirect immunofluorescence assay (IFA) and Western blot. To investigate its immunogenicity, BALB/c mice were immunized with the fusion expression plasmid pCI-VP22-ORF5M and non-fusion expression plasmid pCI-ORF5M, respectively. The GP5-specific ELISA antibodies, neutralizing antibodies and lymphocyte proliferative responses were evaluated at various time points after primary immunization. The results showed that GP5-specific ELISA antibodies, neutralizing antibodies, and lymphocyte proliferative responses induced by DNA vaccine pCI-VP22-ORF5M were higher significantly than those of DNA vaccine pCI-ORF5M, indicating that fusion expression with BHV-1 VP22 significantly enhances the immuogenicity of DNA vaccine expressing the PRRSV GP5 protein, and that this strategy may also be useful to develop more efficient DNA vaccines against other pathogens.
